×
QIAGEN Inventory 2010-2024 | QGEN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
QIAGEN inventory for the quarter ending September 30, 2024 was
$0.322B
, a
19.42% decline
year-over-year.
QIAGEN inventory for 2023 was
$0.398B
, a
11.29% increase
from 2022.
QIAGEN inventory for 2022 was
$0.358B
, a
9.29% increase
from 2021.
QIAGEN inventory for 2021 was
$0.328B
, a
12.48% increase
from 2020.
View More
QIAGEN Inventory 2010-2024 | QGEN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
QIAGEN inventory for 2023 was
$0.398B
, a
11.29% increase
from 2022.
QIAGEN inventory for 2022 was
$0.358B
, a
9.29% increase
from 2021.
QIAGEN inventory for 2021 was
$0.328B
, a
12.48% increase
from 2020.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.2B
Amgen (AMGN)
$160B
Gilead Sciences (GILD)
$137.1B
Vertex Pharmaceuticals (VRTX)
$123.3B
Bristol Myers Squibb (BMY)
$113.2B
CSL (CSLLY)
$80.1B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$76.1B
Argenex SE (ARGX)
$39.3B
Alnylam Pharmaceuticals (ALNY)
$32.5B
BioNTech SE (BNTX)
$28.3B
BeiGene (ONC)
$23.9B
Biogen (BIIB)
$20.1B
Illumina (ILMN)
$15.4B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.9B
Genmab (GNMSF)
$14.7B
Incyte (INCY)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
BioMarin Pharmaceutical (BMRN)
$13.1B
Moderna (MRNA)
$13B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.4B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.3B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.2B
Repligen (RGEN)
$9.1B
Bio-Rad Laboratories (BIO.B)
$8.7B